Shopping Cart
- Remove All
Your shopping cart is currently empty
CCG-1423, a selective RhoA pathway inhibitor, suppresses SRF-mediated transcription.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 mg | $32 | In Stock | |
| 10 mg | $52 | In Stock | |
| 25 mg | $97 | In Stock | |
| 50 mg | $165 | In Stock | |
| 100 mg | $275 | In Stock | |
| 200 mg | $428 | In Stock | |
| 500 mg | $695 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $50 | In Stock |
| Description | CCG-1423, a selective RhoA pathway inhibitor, suppresses SRF-mediated transcription. |
| Targets&IC50 | LRRK2 (G2019S):1.85 nM, LRRK2 (WT):1.28 nM |
| In vivo | In H9c2 cells, CCG-1423 inhibits MRTF nuclear localization and completely blocks the activity of STARS proximal reporter genes. It also suppresses TGF-β-induced fibrogenesis in human colon myofibroblasts. Under the influence of CCG-1423 and LY294002, mouse embryonic stem cells differentiate into the mesendoderm. In melanoma cells (A375M2 and SK-Mel-147) overexpressing RhoC, CCG-1423 selectively inhibits cell proliferation. |
| Cell Research | Cells in normal culture medium are plated (2,000 per well) in a 96-well plate coated with laminin. After attachment, the medium is replaced with serum-free medium (0% FBS) with 30 μmol/L LPA with or without 300 nM CCG-1423. Fresh LPA with or without CCG-1423 is added at day 5 to ensure that LPA and compound are present throughout the experiment. On day 8, WST-1 reagent is added to the wells for 1 h and absorbance at 450 nm is read using a Victor plate reader.(Only for Reference) |
| Synonyms | CCG1423 |
| Molecular Weight | 454.75 |
| Formula | C18H13ClF6N2O3 |
| Cas No. | 285986-88-1 |
| Smiles | CC(ONC(=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C(=O)Nc1ccc(Cl)cc1 |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||||||||||||
| Solubility Information | Ethanol: 4 mg/mL (8.79 mM), Heating is recommended. H2O: < 1 mg/mL (insoluble or slightly soluble) DMSO: 83 mg/mL (182.52 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (7.26 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
Ethanol/DMSO
DMSO
| |||||||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.